Home | OMEGA-UP™ – About | OMEGA-UP™ Clinical Trials on EPA

OMEGA-UP™ Clinical Trials on EPA

Clinical Trials using EPA for Depression, ADHD, Bipolar Disorder, Alzheimer’s Disease, Coronary Artery Disease and Vascular Function

EPA and Depression

Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression.
CONCLUSION: Supplements containing EPA (greater than) ≥ 60% of total EPA + DHA (6:1 or greater), in a dose range of 200 to 2,200 mg/d of EPA in excess of DHA, were effective against primary depression. READ MORE…

EPA and Not DHA for Depression

EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials.
CONCLUSION: The current meta-analysis provides evidence that EPA may be more efficacious than DHA in treating depression. However, owing to the identified limitations of the included studies, larger, well-designed, randomized controlled trials of sufficient duration are needed to confirm these findings. READ MORE…

EPA vs Antidepressants

Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
CONCLUSION: In the present 8 week trial EPA and Antidepressant had equal therapeutic effects in major depressive disorder. EPA + antidepressant combination was superior to either of them alone. READ MORE…


Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis.
CONCLUSION: Omega-3 fatty acid supplementation, particularly with higher doses of EPA, was modestly effective in the treatment of ADHD. READ MORE…

EPA and Alzheimer’s Disease

Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe.
CONCLUSION: The amygdala, which develops neuropathology in the early stage of AD and is involved in the pathogenesis of depression, may be an important brain structure involved in the association between EPA and cognitive decline and depressive symptoms. READ MORE…

EPA and Bipolar Disorder 1

Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study.
CONCLUSION: Although the ultimate utility of omega-3 fatty acids in bipolar depression is still an open question, we believe that these initial results are encouraging, especially for mild to moderate bipolar depression, and justify the continuing exploration of its use. READ MORE…

EPA and Bipolar Disorder 2

Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study.
CONCLUSION: Significant improvement was noted with ethyl-EPA treatment compared with placebo. READ MORE…

EPA and Schizophrenia Preliminary Study

Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study.
CONCLUSION: These findings suggest that an EPA has procognitive effects for patients with schizophrenia, but controlled trials are required. READ MORE…

EPA and Schizophrenia Double Blind Pilot Studies

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.<
CONCLUSION: It is concluded that EPA may represent a new treatment approach to schizophrenia. READ MORE…

EPA and Coronary Artery Disease with Multiple Risk Factors

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors.
CONCLUSION: Multiple risk factors besides cholesterol are associated with markedly increased incidence of CAD. High TG with low HDL-C represents a particularly potent risk factor. EPA was effective in reducing the incidence of CAD events for patients with this dyslipidemic pattern, suggesting that EPA may be especially beneficial in patients who with abnormal TG and HDL-C levels. READ MORE…

EPA and Coronary Artery Disease in Statin Treated Patients

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
CONCLUSION: EPA is effective for secondary prevention of CAD, especially in individuals with prior MI, and should be added to conventional treatment. READ MORE…

EPA and Vascular Function

Administration of highly purified eicosapentaenoic acid (EPA) to statin-treated diabetic patients further improves vascular function.
CONCLUSION: Our results showed that in patients with type 2 diabetes and receiving statin therapy whose LDL-C level was less than 100 mg/dL, the addition of highly purified EPA for 6 months significantly improved vascular function. READ MORE…

EPA and Triglyceride Levels

EPA ethyl ester therapy in patients with very high triglyceride levels.
CONCLUSION: the present randomized, double-blind trial of patients with very high TG levels demonstrated that AMR101 significantly reduced the TG levels and improved other lipid parameters without significantly increasing the LDL cholesterol levels. READ MORE…

EPA and the Recurrence of Strokes

Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial.
CONCLUSION: Administration of highly purified EPA appeared to reduce the risk of recurrent stroke in a Japanese population of hypercholesterolemic patients receiving low-dose statin therapy. Further research is needed to determine whether similar benefits are found in other populations with lower levels of fish intake. The trial is registered at ClinicalTrials.gov (number NCT00231738). READ MORE…

Safety of EPA

Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients.
CONCLUSION: EPA 2 g/day is generally well tolerated. Clinicians should be aware of possible increases in bleeding time, as well as changes in weight and lipid metabolism. READ MORE…



Your Cart